SOUTH SAN FRANCISCO, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis ...
Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer curative potential for HBV INDIANAPOLIS and SAN FRANCISCO, July 09, 2018 (GLOBE NEWSWIRE) -- ...
SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the ...
Prioritization of core inhibitor candidate ABI-4334 and pausing of core inhibitor candidate ABI-H3733 based on data to date from ongoing clinical Phase 1 studies of both candidates and chronic ...
Assembly Bioscience announced the initiation of two randomized control phase 2a trials for ABI-H0731, the company’s lead hepatitis B core inhibitor, according to a press release. ABI-H0731 previously ...
Assembly Biosciences' shares were dragged down more than 20% Wednesday evening after the biotech was forced to toss out a midstage hepatitis B treatment due to safety concerns. The biotech will now ...
Aligos Belgium presented research on ALG-005398, a first representative of a series of non-heteroaryldihydropyrimidines (HAPs) class I capsid-assembly modulators, that was identified using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback